3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
17
Melanoma
3
Glioma
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Multiple Endocrine Neoplasia Type 1
2
Diffuse Intrinsic Pontine Glioma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Rhabdoid Tumor
1
Osteitis Deformans
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Mesothelioma
1
Medulloblastoma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Glioblastoma
1
Familial ependymoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Cystadenocarcinoma, Serous
1
Carcinoma, Hepatocellular
1
Interventions
Temozolomide
14
Bevacizumab
11
Erlotinib Hydrochloride
5
Radiotherapy
4
Carboplatin
4
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Immunoglobulin G
3
Disulfides
3
temsirolimus
2
poly ICLC
2
palbociclib
2
etoposide phosphate
2
antineoplaston AS 2-1
2
antineoplaston A10
2
Vincristine
2
Sunitinib
2
Sirolimus
2
Everolimus
2
Dasatinib
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
veliparib
1
varlilumab
1
vandetanib
1
trebananib
1
trametinib
1
terameprocol
1
tandutinib
1
selinexor
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Oligodendroglioma
×
ribociclib
×
Clear all
No trials found.